Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontorpacept (Primary) ; Nivolumab; Rituximab
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Myelodysplastic syndromes; Myeloproliferative disorders; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Sezary syndrome; Small cell lung cancer; Solid tumours; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

    • Most Recent Events

    • 21 Jul 2023 Number of treatment arms have been reduced from 17 to 16 by the removal of Experimental: Acute Lymphoblastic Leukemia arm. Indications like mycosis fungoides, sezary-syndrome and , Acute-promyelocytic-leukaemia are added.
    • 13 Mar 2023 Status changed from active, no longer recruiting to discontinued. Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.
    • 26 Jul 2022 Planned End Date changed from 1 Dec 2022 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top